Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) Combined with Tumor Whole Exon (WES) Sequencing Technology to Guide Postoperative Adjuvant Treatment Strategy and Prognosis of Colorectal Cancer

NCT05424692 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT05424692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05424692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) Combined with Tumor Whole Exon (WES) Sequencing Technology to Guide Postoperative Adjuvant Treatment Strategy and Prognosis of Colorectal Cancer
Lead sponsor
Peking Union Medical College Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
September 1, 2021
Completion date
September 1, 2027
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy effect, colon cancer, exon mutation, ptc, rectal cancer